ReviewFrontiers in oncology2024
Lipid-based nanoparticles as drug delivery carriers for cancer therapy.
Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 111 citations in OpenAlex.
- Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma.Drug delivery · 2026Article
- Engineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure-Property-Performance Design Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- microRNAs as Regulators of the Immune Response and Their Potential Therapeutic Applications in Cancer.Non-coding RNA · 2026Review
- Immunological Reprogramming by Radiation Therapy: Implications for Precision Cancer Treatment.Immunology · 2026Review
- Mitochondria-Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential.Advanced healthcare materials · 2026Review
- Cancer Drug Delivery with Nanoparticles and Biomolecules: Stimuli-Responsive, Theranostic, and AI-Guided Approaches.Materials (Basel, Switzerland) · 2026Review
- A Multifunctional Chitosan-Coated Ciprofloxacin-Luteolin Lipid Nanoplatform for Photodynamic Therapy of Prostatic Cancer.International journal of molecular sciences · 2026Article
- Theranostic Smart Bionanosensors for Solid Tumors: Advances, Challenges, and Future Directions.Applied biochemistry and biotechnology · 2026Review
- Precision Nanotechnology: Revolutionizing Therapeutic Strategies Against Drug-Resistant Breast Cancer.Annals of biomedical engineering · 2026Review
- Bio-inspired self-assembly of omega-3 fatty acids and peptides for responsive drug delivery.International journal of pharmaceutics: X · 2026Article
- Nanostructured lipid carriers as co-delivery systems for cancer therapy: Prospects and challenges.International journal of pharmaceutics: X · 2026Review
- Nanotherapeutics to Overcome Chemotherapy Resistance in Ovarian Cancer.Pharmaceutical research · 2026Review
- Article
- Human iPSC-derived and conventional cancer models in precision oncology: advancing patient-specific therapies from bench to bedside.Journal of experimental & clinical cancer research : CR · 2026Review
- Advancements in nanobiosensors for early cancer detection, challenges, treatment, and future prospects: a comprehensive review.Discover nano · 2026Review
- Next-Generation Hydrogels Integrating Natural Antioxidants and Microbiome Modulators for Improved Cancer Management.Gels (Basel, Switzerland) · 2026Review
- Platelet-Derived Components for Skin and Bone Aging and Age-Associated Pathologies: Mechanisms, Bioengineering Strategies, and Clinical Translation.Molecules (Basel, Switzerland) · 2026Review
- Engineering Nanocarriers for Dopamine Stabilization and Targeted Brain Delivery: Mechanisms, Approaches and Translational Challenges.International journal of nanomedicine · 2026Review
- Novel stable "sandwich" cyclodextrin inclusion of a lipophilic S-nitrosothiol for controlled delivery of nitric oxide.Materials & design · 2026Article
- MiRNA Regulations in Cardiotoxicity Induced by Oncologic Therapies and Possible Immune Response.Current medicinal chemistry · 2026Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a severe disease that results in death in all countries of the world. A nano-based drug delivery approach is the best alternative, directly targeting cancer tumor cells with improved drug cellular uptake. Different types of nanoparticle-based drug carriers are advanced for the treatment of cancer, and to increase the therapeutic effectiveness and safety of cancer therapy, many substances have been looked into as drug carriers. Lipid-based nanoparticles (LBNPs) have significantly attracted interest recently. These natural biomolecules that alternate to other polymers are frequently recycled in medicine due to their amphipathic properties. Lipid nanoparticles typically provide a variety of benefits, including biocompatibility and biodegradability. This review covers different classes of LBNPs, including their characterization and different synthesis technologies. This review discusses the most significant advancements in lipid nanoparticle technology and their use in medicine administration. Moreover, the review also emphasized the applications of lipid nanoparticles that are used in different cancer treatment types.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.